138 related articles for article (PubMed ID: 26304852)
1. Analysis of Amyloid in Medullary Thyroid Carcinoma by Mass Spectrometry-Based Proteomic Analysis.
Erickson LA; Vrana JA; Theis J; Rivera M; Lloyd RV; McPhail E; Zhang J
Endocr Pathol; 2015 Dec; 26(4):291-5. PubMed ID: 26304852
[TBL] [Abstract][Full Text] [Related]
2. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.
Zhan S; Li J; Wang T; Ge W
Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical comparison of chromogranins A and B and secretogranin II with calcitonin and calcitonin gene-related peptide expression in normal, hyperplastic and neoplastic C-cells of the human thyroid.
Schmid KW; Kirchmair R; Ladurner D; Fischer-Colbrie R; Böcker W
Histopathology; 1992 Sep; 21(3):225-32. PubMed ID: 1356907
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A immunoreactivity compared with argyrophilia, calcitonin immunoreactivity, and amyloid as tumour markers in the histopathological diagnosis of medullary (C-cell) thyroid carcinoma.
Harach HR; Wilander E; Grimelius L; Bergholm U; Westermark P; Falkmer S
Pathol Res Pract; 1992 Feb; 188(1-2):123-30. PubMed ID: 1594480
[TBL] [Abstract][Full Text] [Related]
6. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature.
Bhanot P; Yang J; Schnadig VJ; Logroño R
Diagn Cytopathol; 2007 May; 35(5):285-92. PubMed ID: 17427218
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry of medullary thyroid carcinoma and C-cell hyperplasia by an affinity-purified anti-human calcitonin antiserum.
Hayashida CY; Alves VA; Kanamura CT; Ezabella MC; Abelin NM; Nicolau W; Bisi H; Toledo SP
Cancer; 1993 Aug; 72(4):1356-63. PubMed ID: 8339225
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma.
Pyke CM; Hay ID; Goellner JR; Bergstralh EJ; van Heerden JA; Grant CS
Surgery; 1991 Dec; 110(6):964-70; discussion 970-1. PubMed ID: 1745984
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin-like immunoreactivity of amyloid fibrils in medullary thyroid carcinomas. An immunoelectron microscope study.
Berger G; Berger N; Guillaud MH; Trouillas J; Vauzelle JL
Virchows Arch A Pathol Anat Histopathol; 1988; 412(6):543-51. PubMed ID: 3129866
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
11. Expression of Prox1 in Medullary Thyroid Carcinoma Is Associated with Chromogranin A and Calcitonin Expression and with Ki67 Proliferative Index, but Not with Prognosis.
Saglietti C; La Rosa S; Sykiotis GP; Letovanec I; Bulliard JL; Piana S; Mermod M; Petrova T; Uccella S; Sessa F; Bongiovanni M
Endocr Pathol; 2019 Jun; 30(2):138-145. PubMed ID: 31001799
[TBL] [Abstract][Full Text] [Related]
12. Medullary thyroid carcinoma experienced at Kanazawa University Hospital.
Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Ohtake S; Nakamura S; Ishizaki T
J Surg Oncol; 1996 Jan; 61(1):27-33. PubMed ID: 8544456
[TBL] [Abstract][Full Text] [Related]
13. Familial nonmultiple endocrine neoplasia medullary thyroid carcinoma: an evolving clinical entity.
McHenry CR; Oppenheim DS; Murphy T; Broughan T; Vogt D; Goldfarb WB
Surgery; 1992 Oct; 112(4):728-32; discussion 732-3. PubMed ID: 1411944
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin measurement in fine-needle aspirate washouts vs. cytologic examination for diagnosis of primary or metastatic medullary thyroid carcinoma.
de Crea C; Raffaelli M; Maccora D; Carrozza C; Canu G; Fadda G; Bellantone R; Lombardi CP
Acta Otorhinolaryngol Ital; 2014 Dec; 34(6):399-405. PubMed ID: 25762832
[TBL] [Abstract][Full Text] [Related]
15. PROX1 Promotes Secretory Granule Formation in Medullary Thyroid Cancer Cells.
Ishii J; Yazawa T; Chiba T; Shishido-Hara Y; Arimasu Y; Sato H; Kamma H
Endocrinology; 2016 Mar; 157(3):1289-98. PubMed ID: 26760117
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the amyloid associated with human medullary thyroid carcinoma.
Khurana R; Agarwal A; Bajpai VK; Verma N; Sharma AK; Gupta RP; Madhusudan KP
Endocrinology; 2004 Dec; 145(12):5465-70. PubMed ID: 15459123
[TBL] [Abstract][Full Text] [Related]
17. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome.
Abu-Amero KK; Alzahrani AS; Zou M; Shi Y
Oncogene; 2006 Feb; 25(5):677-84. PubMed ID: 16205644
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma.
Pfragner R; Höfler H; Behmel A; Ingolic E; Walser V
Cancer Res; 1990 Jul; 50(13):4160-6. PubMed ID: 1972348
[TBL] [Abstract][Full Text] [Related]
19. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
20. Family members of patients with sporadic medullary thyroid carcinoma must be screened for hereditary disease.
Olson JE; Hughes J; Alpern HD
Surgery; 1992 Dec; 112(6):1074-8; discussion 1078-9. PubMed ID: 1455309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
